Red blood cell alloimmunisation after platelet transfusion (excluding ABO blood group system)

Area of Science:

• Immunology
• Transfusion Medicine
• Hematology

Background:

• Red blood cell alloimmunization is a known risk associated with red blood cell concentrate transfusions.
• This risk is amplified in specific patient populations, including those with sickle cell disease.
• Alloimmunization is not limited to red blood cell transfusions and can also arise from platelet concentrate transfusions.

Purpose of the Study:

• To highlight the occurrence and implications of red blood cell alloimmunization following both red blood cell and platelet transfusions.
• To emphasize the broad impact across various blood group systems (excluding ABO).
• To underscore the necessity of preventative measures and careful transfusion practices.

Main Methods:

• Review of existing literature on red blood cell alloimmunization.
• Analysis of mechanisms leading to alloimmunization.
• Discussion of clinical implications and preventative strategies.

Main Results:

• Red blood cell alloimmunization can result from both red blood cell and platelet transfusions.
• Multiple blood group systems, beyond ABO, are implicated.
• Significant clinical consequences include the need for antigen-matched transfusions and the risk of hemolytic disease of the fetus and newborn.

Conclusions:

• Alloimmunization is a critical consideration in transfusion medicine, affecting both red blood cell and platelet transfusions.
• Proactive measures, such as antigen matching and prophylactic treatments (e.g., anti-RhD immunoglobulin), are essential for preventing alloimmunization and its sequelae.
• Recognition of these risks is vital for patient management, particularly in pregnant women and individuals with chronic transfusion needs.